Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBT (2021 - 2025)

Senti Biosciences has reported EBT over the past 5 years, most recently at -$18.5 million for Q4 2025.

  • For Q4 2025, EBT fell 16.33% year-over-year to -$18.5 million; the TTM value through Dec 2025 reached -$67.9 million, down 12.91%, while the annual FY2025 figure was -$67.9 million, 12.92% down from the prior year.
  • EBT for Q4 2025 was -$18.5 million at Senti Biosciences, down from -$16.8 million in the prior quarter.
  • Over five years, EBT peaked at -$1178.0 in Q1 2021 and troughed at -$43.3 million in Q3 2023.
  • A 5-year average of -$15.3 million and a median of -$15.4 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: plummeted 997692.87% in 2022 and later surged 65.2% in 2024.
  • Year by year, EBT stood at -$3.9 million in 2021, then tumbled by 306.16% to -$15.7 million in 2022, then dropped by 16.63% to -$18.3 million in 2023, then rose by 12.78% to -$15.9 million in 2024, then decreased by 16.33% to -$18.5 million in 2025.
  • Business Quant data shows EBT for SNTI at -$18.5 million in Q4 2025, -$16.8 million in Q3 2025, and -$16.5 million in Q2 2025.